The prominent bio-tech asset, Edwards Lifesciences Corporation $EW, in the past year has gathered significant investment. Major firms such as Parnassus Investments LLC, SG Americas Securities LLC, Ninety One UK Ltd, Cwm LLC, and others, have increased their stock holdings considerably. TD Cowen has upgraded Edward's stock rating to 'Buy' due to Transcatheter Aortic Valve Replacement (TAVR) growth. Within this same period, share prices have experienced a 14% increase, proving rewarding to investors.
There were some notable events, however, that disrupted Edward's acquisition plans. Their intended acquisition of JenaValve was blocked by the court siding with the FTC. On the brighter side, their product, SAPIEN XT THV, successfully passed a crucial study, and their SAPIEN M3 Mitral Valve Replacement System received FDA approval as the first transcatheter therapy.
While insiders made significant stock sells, there were also substantial purchases. Edwards has shown strong sales growth and increased earnings guidance for 2025, marking notable financial strength. Despite the company achieving strong growth potential, concerns about its high stock price persist. Changes in financial strategy have also emerged, illustrated by a $500 million accelerated share repurchase.
Edwards Lifesciences Corp EW News Analytics from Thu, 24 Apr 2025 07:00:00 GMT to Sat, 10 Jan 2026 19:14:21 GMT - Rating 7 - Innovation 5 - Information 8 - Rumor -7
